Bree, Kelly K.; Hensley, Patrick J.; Brooks, Nathan A.; Matulay, Justin; Li, Roger; Nogueras Gonzalez, Graciela M.; Navai, Neema; Grossman, Herbert Barton; Matin, Surena F.; Dinney, Colin P. N.; Kamat, Ashish M. published an article about the compound: 3,3-Bis(3,5-dibromo-4-hydroxy-2-methylphenyl)-3H-benzo[c][1,2]oxathiole 1,1-dioxide( cas:76-60-8,SMILESS:CC1=C(Br)C(O)=C(Br)C=C1C2(C3=CC(Br)=C(O)C(Br)=C3C)C4=CC=CC=C4S(O2)(=O)=O ).Product Details of 76-60-8. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:76-60-8) through the article.
To evaluate the impact of upper tract urothelial carcinoma (UTUC) on bacillus Calmette-Guerin (BCG) response and progression in patients with non-muscle-invasive bladder cancer (NMIBC). We performed an institutional review board-approved review of patients with NMIBC treated with adequate intravesical BCG, as defined by the US Food and Drug Administration, at our institution between 2000 and 2018. Patients were stratified by presence of any UTUC and time of UTUC diagnosis (preceding vs synchronous to NMIBC diagnosis or metachronous disease after NMIBC diagnosis). Descriptive statistics were used to summarize the data overall and by groups, and t-tests or Wilcoxon’s rank sum tests and Pearson’s chi-squared or Fisher’s exact tests were used to analyze continuous and categorical data, resp. Of 541 patients with NMIBC treated with adequate BCG, 59 (10.9%) were diagnosed with UTUC. Of these, 34 had a history of UTUC prior to NMIBC (UTUC-P; median [interquartile range {IQR}] 13.1 [7.4-27.6] months prior), while 25 developed UTUC after diagnosis of NMIBC (six synchronous and 19 metachronous; median [IQR] 12.1 [1.7-28.1] months after). Compared to the non-UTUC group, patients with UTUC-P were more likely to exhibit Tis without papillary tumor in the bladder (20.6% vs 5.0%; P < 0.001), but were less likely to have T1 disease on index transurethral resection (8.8% vs 49.4%; P < 0.001). Patients with UTUC-P developed more recurrences (55.9% vs 34.0%; P = 0.010), any stage/grade progression (23.5% vs 9.8%; P = 0.012) and progression to muscle-invasive or metastatic disease (17.6% vs 6.4%; P = 0.014). The presence of high-grade UTUC-P compared to low-grade UTUC-P was associated with increased NMIBC recurrence (68.2% vs 25.0%; P = 0.049). There was no significant difference in rates of recurrence or progression based on timing of UTUC with respect to the index bladder tumor, although this anal. was limited by small numbers Presence of UTUC prior to a diagnosis of NMIBC was associated with an almost twofold increased recurrence and progression rates after adequate BCG therapy. This should be considered when counselling patients and designing cohorts for clin. trials. Although many compounds look similar to this compound(76-60-8)Product Details of 76-60-8, numerous studies have shown that this compound(SMILES:CC1=C(Br)C(O)=C(Br)C=C1C2(C3=CC(Br)=C(O)C(Br)=C3C)C4=CC=CC=C4S(O2)(=O)=O), has unique advantages. If you want to know more about similar compounds, you can read my other articles.
Reference:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles